Skip to main navigation
Syndax Pharmaceuticals, Inc. logo
  • About Us
    • About Us
    • Leadership
    • Board of Directors
    • Patient Community
  • Focus Areas
    • Focus Areas
    • KMT2Ar Acute Leukemias
    • NPM1m Acute Myeloid Leukemia
    • Chronic Graft-Versus-Host Disease
  • Pipeline
    • Pipeline
    • Menin Inhibitor
    • Anti-CSF-1R Monoclonal Antibody
    • Entinostat
    • Publications & Meeting Presentations
  • Our Products
  • Patients
    • Patients
    • Managed Access Programs
  • Investors
  • Careers
  • News
  • Contact Us

SEC Filing Details

Investors
  • Home
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Governance Overview
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • Financial Overview
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
    • Analyst Consensus
  • Shareholder Services
    • Investor FAQs
    • Contact Us
    • RSS Feeds
    • Email Alerts

Document Details

Form
S-8
Filing Date
Feb 26, 2026
Document Date
Feb 26, 2026
Form Description
Securities offered to employees pursuant to employee benefit plans
Filing Group
Registration Statements
Company
Syndax Pharmaceuticals, Inc.
Issuer
Syndax Pharmaceuticals Inc

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
XML - XBRL INSTANCE DOCUMENT
Syndax Pharmaceuticals, Inc. logo
  • About Us
  • Focus Areas
  • Pipeline
  • Our Products
  • Patients
  • Investors
  • Careers
  • News
  • Contact Us
Privacy Notice
Cookie Notice
Consumer Health Data Supplemental Privacy Notice
State Regulations
Terms of Use
Limit the Use of My Personal Information
© 2026 Syndax Pharmaceuticals, Inc.
linkedin x.com glassdoor